AU2015311805B2 - Inhibitors of lysine specific demethylase-1 - Google Patents

Inhibitors of lysine specific demethylase-1 Download PDF

Info

Publication number
AU2015311805B2
AU2015311805B2 AU2015311805A AU2015311805A AU2015311805B2 AU 2015311805 B2 AU2015311805 B2 AU 2015311805B2 AU 2015311805 A AU2015311805 A AU 2015311805A AU 2015311805 A AU2015311805 A AU 2015311805A AU 2015311805 B2 AU2015311805 B2 AU 2015311805B2
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
benzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015311805A
Other languages
English (en)
Other versions
AU2015311805A1 (en
Inventor
Young K. Chen
Toufike Kanouni
Jeffrey Alan Stafford
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of AU2015311805A1 publication Critical patent/AU2015311805A1/en
Application granted granted Critical
Publication of AU2015311805B2 publication Critical patent/AU2015311805B2/en
Priority to AU2020204287A priority Critical patent/AU2020204287A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015311805A 2014-09-05 2015-09-03 Inhibitors of lysine specific demethylase-1 Ceased AU2015311805B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020204287A AU2020204287A1 (en) 2014-09-05 2020-06-26 Inhibitors of lysine specific demethylase-1

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046842P 2014-09-05 2014-09-05
US62/046,842 2014-09-05
PCT/US2015/048429 WO2016037005A1 (en) 2014-09-05 2015-09-03 Inhibitors of lysine specific demethylase-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204287A Division AU2020204287A1 (en) 2014-09-05 2020-06-26 Inhibitors of lysine specific demethylase-1

Publications (2)

Publication Number Publication Date
AU2015311805A1 AU2015311805A1 (en) 2017-03-23
AU2015311805B2 true AU2015311805B2 (en) 2020-04-02

Family

ID=55440376

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015311805A Ceased AU2015311805B2 (en) 2014-09-05 2015-09-03 Inhibitors of lysine specific demethylase-1
AU2020204287A Abandoned AU2020204287A1 (en) 2014-09-05 2020-06-26 Inhibitors of lysine specific demethylase-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020204287A Abandoned AU2020204287A1 (en) 2014-09-05 2020-06-26 Inhibitors of lysine specific demethylase-1

Country Status (17)

Country Link
US (3) US9822119B2 (OSRAM)
EP (1) EP3189038B1 (OSRAM)
JP (2) JP6692350B2 (OSRAM)
KR (1) KR102476459B1 (OSRAM)
CN (2) CN112125901A (OSRAM)
AU (2) AU2015311805B2 (OSRAM)
BR (1) BR112017004334A2 (OSRAM)
CA (1) CA2960188A1 (OSRAM)
CL (1) CL2017000521A1 (OSRAM)
CO (1) CO2017002191A2 (OSRAM)
EA (1) EA201790376A1 (OSRAM)
EC (1) ECSP17013466A (OSRAM)
ES (1) ES2935114T3 (OSRAM)
IL (1) IL250876B (OSRAM)
MX (1) MX381597B (OSRAM)
SG (2) SG10202008486SA (OSRAM)
WO (1) WO2016037005A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125901A (zh) * 2014-09-05 2020-12-25 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂
CA2987876A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
PL3381896T3 (pl) 2015-11-27 2023-05-08 Taiho Pharmaceutical Co., Ltd. Związek bifenylowy lub jego sól
SG11201805645QA (en) 2015-12-29 2018-07-30 Mirati Therapeutics Inc Lsd1 inhibitors
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN105924397B (zh) * 2016-04-29 2017-11-24 河南省农业科学院植物保护研究所 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途
HUE057838T2 (hu) * 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
PE20190624A1 (es) * 2016-07-12 2019-04-26 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CA3065077C (en) * 2017-05-26 2022-09-20 Taiho Pharmaceutical Co., Ltd. Novel biphenyl compound or salt thereof
MA50467A (fr) 2017-05-26 2020-09-02 Taiho Pharmaceutical Co Ltd Potentialisateur d'effet antitumoral utilisant un nouveau composé biphényle
US12435128B2 (en) 2017-05-31 2025-10-07 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
LT3661510T (lt) 2017-08-03 2025-01-27 Oryzon Genomics, S.A. Elgesio pakitimų gydymo būdai
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CN120837494A (zh) 2019-03-20 2025-10-28 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
US20220249528A1 (en) 2019-06-20 2022-08-11 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
BR112022008020A2 (pt) 2019-11-13 2022-07-12 Taiho Pharmaceutical Co Ltd Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
EP4306520A4 (en) * 2021-03-11 2025-05-07 Medshine Discovery Inc. THIOPHENE COMPOUND AND ITS USE
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
EP4419504A4 (en) * 2021-10-18 2025-09-03 Imago Biosciences Inc KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
CN113968824B (zh) * 2021-11-29 2024-01-19 郑州大学 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用
WO2023142641A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种吡啶类衍生物、其制备方法及用途
CN116836167B (zh) * 2022-03-25 2025-09-09 腾讯科技（深圳）有限公司 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024208187A1 (zh) * 2023-04-03 2024-10-10 上海复星医药（集团）股份有限公司 氮杂芳基化合物及其作为lsd1抑制剂的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317698A1 (en) * 2006-01-30 2010-12-16 Les Laboratoires Servier Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
WO2015089192A1 (en) * 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1397142A4 (en) * 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
CA2506568A1 (en) * 2002-11-22 2004-06-10 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
CA2560346A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
JP2008536950A (ja) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
AU2009275957A1 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
EP2258865A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
BR112012016178A2 (pt) * 2009-12-31 2015-10-06 Piramal Healthcare Ltd inibidores de diacilglicerol aciltransferase
US8765820B2 (en) 2010-04-20 2014-07-01 Universita Degli Studi Di Roma “La Sapienza” Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
US9006449B2 (en) * 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
KR101351919B1 (ko) 2012-05-23 2014-01-24 현대모비스 주식회사 차선 유지 보조 시스템 및 방법
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
AR098203A1 (es) 2013-11-13 2016-05-18 Dow Global Technologies Llc Reactivo de ensayo de formaldehído
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN112125901A (zh) * 2014-09-05 2020-12-25 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317698A1 (en) * 2006-01-30 2010-12-16 Les Laboratoires Servier Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
WO2015089192A1 (en) * 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTELLE DOEBELIN ET AL, "Fully regiocontrolled polyarylation of pyridine", THE JOURNAL OF ORGANIC CHEMISTRY, (2014-01-13), vol. 79, no. 3, doi:10.1021/jo402200q, ISSN 0022-3263, pages 908 - 918 *
DAVID J. WUSTROW ET AL, "Aminopyrazine CB1 receptor inverse agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 11, doi:10.1016/J.BMCL.2008.04.022, ISSN 0960-894X, (2008), pages 3376 - 3381, (2008-04-13) *
EDWIN C. CONSTABLE ET AL, "4-Substituted and 4,5-disubstituted 3,6-di(2-pyridyl)pyridazines: ligands for supramolecular assemblies", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, (2008), vol. 2008, no. 9, pages 1597 - 1607 *
JAMES R. HITCHIN ET AL, "Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments", MEDCHEMCOMM, (2013), vol. 4, no. 11, doi:10.1039/c3md00226h, ISSN 2040-2503, pages 1513 - 1522 *

Also Published As

Publication number Publication date
ECSP17013466A (es) 2017-05-31
EP3189038A4 (en) 2018-02-28
JP6692350B2 (ja) 2020-05-13
CN107074787A (zh) 2017-08-18
EP3189038A1 (en) 2017-07-12
CA2960188A1 (en) 2016-03-10
US20180028508A1 (en) 2018-02-01
IL250876A0 (en) 2017-04-30
CN107074787B (zh) 2020-10-27
SG11201701683XA (en) 2017-04-27
CO2017002191A2 (es) 2017-05-19
JP2017527561A (ja) 2017-09-21
US20160108046A1 (en) 2016-04-21
EP3189038B1 (en) 2022-11-23
ES2935114T3 (es) 2023-03-01
BR112017004334A2 (pt) 2018-08-07
MX2017002824A (es) 2017-05-30
SG10202008486SA (en) 2020-09-29
MX381597B (es) 2025-03-12
KR102476459B1 (ko) 2022-12-09
CN112125901A (zh) 2020-12-25
AU2020204287A1 (en) 2020-07-16
WO2016037005A1 (en) 2016-03-10
KR20170045342A (ko) 2017-04-26
AU2015311805A1 (en) 2017-03-23
US10543198B2 (en) 2020-01-28
US9822119B2 (en) 2017-11-21
EA201790376A1 (ru) 2017-08-31
US20200108052A1 (en) 2020-04-09
CL2017000521A1 (es) 2017-11-03
JP6983273B2 (ja) 2021-12-17
JP2020125321A (ja) 2020-08-20
IL250876B (en) 2021-09-30
US10864202B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
AU2015311805B2 (en) Inhibitors of lysine specific demethylase-1
US10385051B2 (en) Inhibitors of lysine specific demethylase-1
AU2019261771B2 (en) Inhibitors of lysine specific demethylase-1
AU2015253040B2 (en) Inhibitors of lysine specific demethylase-1
EA036172B1 (ru) Спирогептансалициламиды и родственные соединения как ингибиторы rock
EP4161656A1 (en) Inhibitors of fibroblast growth factor receptor kinases
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
EP4161657A1 (en) Inhibitors of fibroblast growth factor receptor kinases
HK1230202B (en) Inhibitors of lysine specific demethylase-1
HK1230202A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired